Episode 30: A Conversation on Obesity with Dr. Naser E. Gharaibeh, Medical Director, Valley Health System Center for Weight and Wellness, New Jersey

2025-02-18

UPDATE: The Trump administration has decided Medicare will NOT pay for the popular GLP-1 drugs just for weight loss. It would have cost the government nearly $40 Billion over 10 years. Perhaps the hottest, most divisive topic in health care is obesity. Which in the US appears to have stabilized in 2024 at about 40% of adults. Is obesity a disease or a lifestyle result? How does it affect overall health and what diseases can it cause? Who should take the expensive new GLP-1 weight loss ...

UPDATE: The Trump administration has decided Medicare will NOT pay for the popular GLP-1 drugs just for weight loss. It would have cost the government nearly $40 Billion over 10 years.

Perhaps the hottest, most divisive topic in health care is obesity. Which in the US appears to have stabilized in 2024 at about 40% of adults. Is obesity a disease or a lifestyle result? How does it affect overall health and what diseases can it cause? Who should take the expensive new GLP-1 weight loss drugs like Wegovy? And perhaps the most divisive issue - who should pay for those drugs – and how. Get ready for a great conversation with tons of useful information from my guest Dr. Naser Gharaibeh, MD, CPE, DABOM, NCMP – who heads the Valley Health System Center for Weight and Wellness in New Jersey. Dr. Gharaibeh is board certified in obesity medicine as well as endocrinology, diabetes, metabolism and internal medicine.

Note: all episodes are also available in video form on YouTube

Comments (3)